CVRx reports on ‘significant reductions in healthcare utilization’ with Barostim

CVRx (CVRX) announced the presentation of new real-world evidence at the Technology and Heart Failure Therapeutics conference in Boston. “The study demonstrated large and statistically significant reductions in hospital visits and length of stay after Barostim implantation, compared to before,” the company stated. The research was published simultaneously and is available now in the Journal of Cardiac Failure. “Congratulations to Dr. Jacob Abraham and co-authors for this important real-world analysis demonstrating remarkable reductions in healthcare utilization with Barostim. We believe this study adds to the growing and consistent body of evidence supporting the clinical utility of Barostim. This is another example of our commitment to further develop and disseminate a strong pipeline of clinical and economic data supporting the many benefits of this therapy,” said Dr. Philip Adamson, Chief Medical Officer of CVRx.